[go: up one dir, main page]

AR113275A1 - Compuestos de cefem con grupos reactivos latentes - Google Patents

Compuestos de cefem con grupos reactivos latentes

Info

Publication number
AR113275A1
AR113275A1 ARP180102869A ARP180102869A AR113275A1 AR 113275 A1 AR113275 A1 AR 113275A1 AR P180102869 A ARP180102869 A AR P180102869A AR P180102869 A ARP180102869 A AR P180102869A AR 113275 A1 AR113275 A1 AR 113275A1
Authority
AR
Argentina
Prior art keywords
compounds
penems
leaving group
cephemes
activity against
Prior art date
Application number
ARP180102869A
Other languages
English (en)
Original Assignee
Gladius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gladius Pharmaceuticals Inc filed Critical Gladius Pharmaceuticals Inc
Publication of AR113275A1 publication Critical patent/AR113275A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/577-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with a further substituent in position 7, e.g. cephamycines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Compuestos de cefem y penem que tienen un resto estirilmetileno en la posición 3 en el anillo de cefem o penem al que está unido un grupo saliente cargado positivamente y donde el grupo saliente contiene un diol vecino o está unido a un catecol no sustituido o sustituido. El grupo saliente puede ser un grupo saliente de nitrógeno con carga positiva. Las cefemas incluyen cefalosporinas, cefamicinas, carbacefemas y oxacefemas. Los penems incluyen penems, carbapenems y oxapenems. Las cefemas preferidas son cefalosporinas. Los penems preferidos son carbapenems. Los compuestos exhiben actividad antibiótica contra bacterias gramnegativas y/o bacterias grampositivas. Los compuestos exhiben actividad antibiótica contra bacterias que exhiben resistencia a múltiples fármacos. Los compuestos de la presente exhiben actividad antibiótica contra cepas bacterianas que producen b-lactamasas de espectro extendido (ESBL), que producen AmpC b-lactamasas o que producen una carbapenemasa. Composiciones farmacéuticas que comprenden una o más cefemas o penems o métodos de tratamiento de infecciones bacterianas con dichos compuestos y composiciones.
ARP180102869A 2017-10-04 2018-10-04 Compuestos de cefem con grupos reactivos latentes AR113275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762568104P 2017-10-04 2017-10-04

Publications (1)

Publication Number Publication Date
AR113275A1 true AR113275A1 (es) 2020-03-11

Family

ID=65895920

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102869A AR113275A1 (es) 2017-10-04 2018-10-04 Compuestos de cefem con grupos reactivos latentes

Country Status (4)

Country Link
US (1) US20190100534A1 (es)
AR (1) AR113275A1 (es)
TW (1) TW201922755A (es)
WO (1) WO2019070973A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020206381A1 (en) * 2019-04-03 2020-10-08 Sutton Larry D Cephem compounds with latent reactive groups and methods of using and making same
CN110950893B (zh) * 2019-12-03 2022-01-07 华南理工大学 一种多功能荧光探针及其制备方法和应用
CN118598802B (zh) * 2024-08-07 2024-12-06 蒲城驭腾新材料科技有限公司 一种吡啶季铵盐型全氟烃基醚化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2526046B2 (ja) * 1986-12-26 1996-08-21 サントリー株式会社 ペネム誘導体、その製造法およびその用途
DE3839987A1 (de) * 1988-11-26 1990-05-31 Hoechst Ag Penemderivate und verfahren zu ihrer herstellung
CA2089366C (en) * 1990-08-20 2001-10-16 Hiromitsu Iwata Penem compounds
US6271222B1 (en) * 1998-05-28 2001-08-07 Merck & Co., Inc. Penem antibacterial compounds, compositions and methods of treatment
US8883772B2 (en) * 2007-10-09 2014-11-11 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
US20100261700A1 (en) * 2009-04-09 2010-10-14 Larry Sutton Beta-lactamase inhibitors
ES2700575T3 (es) * 2013-03-12 2019-02-18 Gladius Pharmaceuticals Corp 3-Estiril-cefalosporinas derivadas

Also Published As

Publication number Publication date
WO2019070973A1 (en) 2019-04-11
TW201922755A (zh) 2019-06-16
US20190100534A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
Elshamy et al. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options
Girija et al. Prevalence of carbapenem-hydrolyzing OXA-type β-lactamases among Acinetobacter baumannii in patients with severe urinary tract infection
Pop-Vicas et al. The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock
Tissera et al. Isolation of extended spectrum β-lactamase (ESBL) producing bacteria from urban surface waters in Malaysia
CO6331438A2 (es) Inhibidores de beta-lactamasa
AR113275A1 (es) Compuestos de cefem con grupos reactivos latentes
Bedenić et al. Molecular characterization of class b carbapenemases in advanced stage of dissemination and emergence of class d carbapenemases in Enterobacteriaceae from Croatia
EA201890150A1 (ru) 3-тетразолил-бензол-1,2-дисульфонамидные производные в качестве ингибиторов металло-бета-лактамазы
RU2014109447A (ru) Азотсодержащие соединения и их применение
MX2019013260A (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.
Bhaskar et al. Molecular characterization of extended spectrum β-lactamase and carbapenemase producing Klebsiella pneumoniae from a tertiary care hospital
Cicora et al. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study
Bae et al. Molecular epidemiology of Pseudomonas aeruginosa clinical isolates from Korea producing β-lactamases with extended-spectrum activity
Pobiega et al. Molecular characterization of carbapenem-resistant Pseudomonas aeruginosa strains isolated from patients with urinary tract infections in Southern Poland
Kamruzzaman et al. Genetic diversity and antibiotic resistance in Escherichia coli from environmental surface water in Dhaka City, Bangladesh
Tavajjohi et al. Detection and characterization of multidrug resistance and extended-spectrum-beta-lactamase-producing (ESBLS) Pseudomonas aeruginosa isolates in teaching hospital
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
Abate et al. Cedecea davisae bacteremia in a neutropenic patient with acute myeloid leukemia
Bielen et al. Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study
Mitsuwan et al. Occurrence of multidrug resistance associated with extended-spectrum β‑lactamase and the biofilm forming ability of Escherichia coli in environmental swine husbandry
Rout et al. Surveillance of extended-spectrum β-lactamase producing bacteria in an Indian teaching hospital
TW200716104A (en) Tricyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
Okwu et al. Prevalence and antimicrobial susceptibility profiles of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) isolates among healthy individuals in Okada, South-South, Nigeria
Shahid et al. Molecular epidemiology of carbapenem-resistant Enterobacteriaceae from a North Indian Tertiary Hospital
Taheri et al. Antibiotic resistance pattern and phylogenetic groups of the Uropathogenic Escherichia coli isolates recovered from the urinary catheters of the hospitalized patients

Legal Events

Date Code Title Description
FB Suspension of granting procedure